MYELOID NEOPLASIA The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling
نویسندگان
چکیده
1Department of Microbiology, Institute of Clinical Biochemistry and Centre of Molecular Biology and Neuroscience, Oslo University Hospital and University of Oslo, Rikshospitalet, Oslo, Norway; 2Department of Biomedicine, University of Bergen, Bergen, Norway; 3Department of Biochemistry, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; 4Section for Haematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway; and 5NorLux Neuro-oncology Laboratory, Department of Biomedicine, University of Bergen, Bergen, Norway and NorLux Neuro-oncology Laboratory, Centre de Recherche Public de la Santé, Luxembourg, Luxembourg
منابع مشابه
The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Arsenic in the form of arsenic trioxide (ATO) is used as a therapeutic drug for treatment of acute promyelocytic leukemia (APL). The mechanism by which this agent cures this disease was previously shown to involve direct interactions between ATO and the promyelocytic leukemia protein (PML), as well as accelerated degradation of the APL-associated fusion oncoprotein PML/retinoic acid receptor α ...
متن کاملCytogenetic and FMS-Like Tyrosine Kinase 3 Mutation Analyses in Acute Promyelocytic Leukemia Patients
Background: The secondary genetic changes other than the promyelocytic leukemia-retinoic acid receptor (PML-RARA) fusion gene may contribute to the acute promyelocytic leukemogenesis. Chromosomal alterations and mutation of FLT3 (FMS-like tyrosine kinase 3) tyrosine kinase receptor are the frequent genetic alterations in acute myeloid leukemia. However, the prognostic significance of FLT3 mutat...
متن کاملMYELOID NEOPLASIA Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein
Treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid and/or arsenic trioxide represents a paradigm in targeted cancer therapy because these drugs cause clinical remission by affecting the stability of the fusion oncoprotein promyelocytic leukemia (PML)/ retinoic acid receptor alpha (RARA). The authors of previous studies have implicated the ubiquitin-proteasome pathway a...
متن کاملAcute promyelocytic leukemia, arsenic, and PML bodies
Acute promyelocytic leukemia (APL) is driven by a chromosomal translocation whose product, the PML/retinoic acid (RA) receptor α (RARA) fusion protein, affects both nuclear receptor signaling and PML body assembly. Dissection of APL pathogenesis has led to the rediscovery of PML bodies and revealed their role in cell senescence, disease pathogenesis, and responsiveness to treatment. APL is rema...
متن کاملSpecific Inhibition of the Expression of the Promyelocytic Leukemia (PML) Protein by Anti-Sense Oligonucleotides
In the present study, using anti-sense oligonucleotides the inhibition of expression of the PML protein hasbeen investigated. The anti-sense oligonucleotides were designed against the translation initiation site ofthe PML gene, and their effects were investigated on cellular growth and DNA synthesis. Incubation of normalhuman fibroblast cells with the anti-sense oligonucleotid...
متن کامل